-
US faces tough path to new Iran nuclear deal
-
Good US Open shots not good enough for 2-over Scheffler
-
Cuba unveils historic package of free-market reforms
-
Subs send Swiss to World Cup rout of Bosnia-Herzegovina
-
Stokes set for England return in New Zealand finale - reports
-
McIlroy pleased with reduced green speeds in US Open winds
-
Quarantine over for almost all hantavirus ship passengers, crew
-
US stocks resume upward climb as dollar advances again after Fed outlook
-
Ex-presidents and stars, but no Trump, turn out for Obama Library
-
Stevens seizes US Open lead with McIlroy, Aberg one back
-
Al-Qaeda-linked jihadists attack Niger airport, 11 soldiers killed
-
'Big-game' Bellingham shows his worth for England at World Cup
-
New Zealand's Henry rocks England in 2nd Test after Phillips century
-
Vance warns Israel against criticizing US-Iran deal
-
Iran's supreme leader says approved deal as US lifts ports blockade
-
Australian qualifier Hijikata shocks Lehecka at Queen's Club
-
AI-generated videos use Down syndrome to make sales
-
O'Brien's royal century reward for sacrificing all for racing
-
Spurs sign Dutch defender Van Hecke from Brighton
-
England great Botham slams Stokes for breaking curfew
-
Liverpool agree deal to sign Spain forward Munoz from Osasuna
-
Chivu extends Inter deal until 2028 after debut season double triumph
-
New Zealand's Henry rocks England after Phillips century
-
Ghana pushes for concrete slavery reparations
-
Wildcard Eala shocks Rybakina in Berlin
-
Robertson and Scotland eye World Cup history against Morocco
-
South Africa hold Czechs, keep World Cup knockout dream alive
-
Joyful New York celebrates Knicks with ticker-tape parade
-
Important or selfish? World Cup evidence mounts against Ronaldo
-
Europe risks 'total irrelevance' without sovereign tech: Cohere chief
-
Ex-presidents, stars, but no Trump, turn out for Obama Center
-
Vance defends Iran deal, eyes Swiss talks
-
US Olympic athlete Simpson shows 'improvement' after collasing on track
-
Wahi granted Canadian visa for Ivory Coast World Cup match after delay
-
Israel FM cuts contact with EU top diplomat over 'apartheid' remarks
-
US lifts Iran ports blockade as uncertainty clouds Swiss Iran talks
-
Brazilian police probe senator close to Lula
-
Brutal Shinnecock winds blow away US Open contenders
-
Leverkusen sign Portuguese talent Moreira from Lyon
-
AI-generated videos wield Down syndrome to make sales
-
Suspected jihadists stage deadly new attack on Niger airport
-
Man dies, trains and classes disrupted as heatwave hits France
-
Oil sinks on Mideast deal, but Fed outlook knocks equities
-
Neymar to miss Brazil's second World Cup game against Haiti
-
Dupont to start for Toulouse in Top 14 semi, Ramos out
-
O'Brien's historic 100th Royal Ascot winner has golden glow
-
Zverev wins all-German duel with Hanfmann to reach Halle quarters
-
Graft probe into Spanish ex-PM expanded to daughters
-
Iran war leaves Islamic republic intact and opponents divided
-
Gregoire wins Swiss tour 2nd stage as Pogacar extends lead
From Covid to cancer: High hopes for Nobel mRNA vaccines
The coronavirus pandemic brought global renown to the mRNA technology that underpins vaccines from Pfizer/BioNTech and Moderna, and on Monday earned a Nobel Prize for two scientists who have been key to its development.
Katalin Kariko of Hungary and Drew Weissman of the United States won the Nobel Medicine Prize for their work on "nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".
These types of jabs are new but researchers have been working for decades to try to figure out how to use messenger RNA (ribonucleic acid) for other vaccinations and to treat illnesses from AIDS to cancer.
- How does it work? -
Messenger RNA's job in the body is to help deliver specific instructions from DNA to cells.
In the case of the Pfizer/BioNTech and Moderna jabs, lab-generated mRNA tells human cells to create antigens -- proteins that are similar to ones found in the Covid-19 virus.
Thanks to those antigens, a person's immune system learns how to fight the virus and neutralise Covid if it enters the body.
After the cells create these proteins, the body breaks down the mRNA instructions and gets rid of them.
Such direct communication with cells is revolutionary -- classic vaccines aimed to provoke an immune response by injecting a neutralised form of a virus or antigens into the system.
- Where did this come from? -
The first big breakthrough, in the late 1970s, was in using mRNA to make test-tube cells produce proteins.
A decade later, scientists were able to get the same results in mice, but mRNA still had two major drawbacks as a medical tool.
For one thing, cells in live animals resisted synthetic mRNA, provoking a dangerous immune response.
On top of that, mRNA molecules are fragile, making them difficult to deliver to the system without altering them.
In 2005, Kariko and Weissman of Penn State University published a groundbreaking study showing that a lipid -- or fat molecule -- envelope could safely deliver mRNA without negative effects.
The research caused a buzz in the pharmaceutical community and start-ups dedicated to mRNA therapies began to pop up around the world.
- What else can mRNA do? -
Scientists have worked on developing mRNA jabs for illnesses like seasonal flu, rabies and Zika, as well as those that have remained vaccine-resistant until now, including malaria and AIDS.
Researchers have also started testing personalised treatments on cancer patients, using samples of the proteins in their tumours to create specialised mRNA.
This then triggers the immune system to target specific cancer cells.
"The mRNA platform is versatile," University of Pennsylvania biochemist Norbert Pardi told AFP. "Any protein can be encoded as mRNA so there are many potential applications."
G.Stevens--AMWN